Logo image of NRIX

NURIX THERAPEUTICS INC (NRIX) Stock Fundamental Analysis

NASDAQ:NRIX - Nasdaq - US67080M1036 - Common Stock - Currency: USD

16.87  -0.17 (-1%)

After market: 16.92 +0.05 (+0.3%)

Fundamental Rating

4

Overall NRIX gets a fundamental rating of 4 out of 10. We evaluated NRIX against 572 industry peers in the Biotechnology industry. NRIX has a great financial health rating, but its profitability evaluates not so good. NRIX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NRIX had negative earnings in the past year.
In the past year NRIX has reported a negative cash flow from operations.
NRIX had negative earnings in each of the past 5 years.
NRIX had a negative operating cash flow in each of the past 5 years.
NRIX Yearly Net Income VS EBIT VS OCF VS FCFNRIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With a decent Return On Assets value of -28.92%, NRIX is doing good in the industry, outperforming 70.16% of the companies in the same industry.
With a decent Return On Equity value of -36.73%, NRIX is doing good in the industry, outperforming 73.71% of the companies in the same industry.
Industry RankSector Rank
ROA -28.92%
ROE -36.73%
ROIC N/A
ROA(3y)-37.56%
ROA(5y)-29.63%
ROE(3y)-55.97%
ROE(5y)-43.41%
ROIC(3y)N/A
ROIC(5y)N/A
NRIX Yearly ROA, ROE, ROICNRIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 200

1.3 Margins

NRIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRIX Yearly Profit, Operating, Gross MarginsNRIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

8

2. Health

2.1 Basic Checks

NRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NRIX has been increased compared to 1 year ago.
Compared to 5 years ago, NRIX has more shares outstanding
There is no outstanding debt for NRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NRIX Yearly Shares OutstandingNRIX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NRIX Yearly Total Debt VS Total AssetsNRIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 3.88 indicates that NRIX is not in any danger for bankruptcy at the moment.
NRIX has a Altman-Z score of 3.88. This is in the better half of the industry: NRIX outperforms 77.09% of its industry peers.
There is no outstanding debt for NRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.88
ROIC/WACCN/A
WACC9.44%
NRIX Yearly LT Debt VS Equity VS FCFNRIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 6.46 indicates that NRIX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.46, NRIX is in the better half of the industry, outperforming 64.30% of the companies in the same industry.
A Quick Ratio of 6.46 indicates that NRIX has no problem at all paying its short term obligations.
NRIX has a better Quick ratio (6.46) than 64.48% of its industry peers.
Industry RankSector Rank
Current Ratio 6.46
Quick Ratio 6.46
NRIX Yearly Current Assets VS Current LiabilitesNRIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for NRIX have decreased by -9.06% in the last year.
The Revenue for NRIX has decreased by -29.16% in the past year. This is quite bad
NRIX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.88% yearly.
EPS 1Y (TTM)-9.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.6%
Revenue 1Y (TTM)-29.16%
Revenue growth 3Y22.4%
Revenue growth 5Y11.88%
Sales Q2Q%-12.37%

3.2 Future

Based on estimates for the next years, NRIX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.72% on average per year.
The Revenue is expected to grow by 51.49% on average over the next years. This is a very strong growth
EPS Next Y-9.65%
EPS Next 2Y-6.69%
EPS Next 3Y-4.97%
EPS Next 5Y16.72%
Revenue Next Year1.15%
Revenue Next 2Y3.9%
Revenue Next 3Y16.85%
Revenue Next 5Y51.49%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NRIX Yearly Revenue VS EstimatesNRIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
NRIX Yearly EPS VS EstimatesNRIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NRIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRIX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRIX Price Earnings VS Forward Price EarningsNRIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRIX Per share dataNRIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as NRIX's earnings are expected to decrease with -4.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.69%
EPS Next 3Y-4.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NURIX THERAPEUTICS INC

NASDAQ:NRIX (2/21/2025, 8:00:01 PM)

After market: 16.92 +0.05 (+0.3%)

16.87

-0.17 (-1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-28 2025-01-28/amc
Earnings (Next)04-08 2025-04-08/bmo
Inst Owners106.41%
Inst Owner Change19.86%
Ins Owners1.41%
Ins Owner Change-0.11%
Market Cap1.28B
Analysts85
Price Target33.06 (95.97%)
Short Float %14.7%
Short Ratio14.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.53%
Min EPS beat(2)-8.65%
Max EPS beat(2)7.58%
EPS beat(4)2
Avg EPS beat(4)-0.9%
Min EPS beat(4)-9.62%
Max EPS beat(4)7.58%
EPS beat(8)5
Avg EPS beat(8)1.53%
EPS beat(12)6
Avg EPS beat(12)0.58%
EPS beat(16)6
Avg EPS beat(16)-3.58%
Revenue beat(2)2
Avg Revenue beat(2)1.88%
Min Revenue beat(2)1.28%
Max Revenue beat(2)2.47%
Revenue beat(4)2
Avg Revenue beat(4)-11.23%
Min Revenue beat(4)-46.37%
Max Revenue beat(4)2.47%
Revenue beat(8)5
Avg Revenue beat(8)-5.49%
Revenue beat(12)7
Avg Revenue beat(12)-9.1%
Revenue beat(16)8
Avg Revenue beat(16)-11.89%
PT rev (1m)0%
PT rev (3m)3.82%
EPS NQ rev (1m)-9.91%
EPS NQ rev (3m)2.62%
EPS NY rev (1m)-9.31%
EPS NY rev (3m)-11.93%
Revenue NQ rev (1m)-18.67%
Revenue NQ rev (3m)-26.1%
Revenue NY rev (1m)-2.55%
Revenue NY rev (3m)-5.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.47
P/FCF N/A
P/OCF N/A
P/B 2.43
P/tB 2.43
EV/EBITDA N/A
EPS(TTM)-2.89
EYN/A
EPS(NY)-3.17
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.27
OCFYN/A
SpS0.72
BVpS6.94
TBVpS6.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.92%
ROE -36.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.56%
ROA(5y)-29.63%
ROE(3y)-55.97%
ROE(5y)-43.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.45%
Cap/Sales 17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.46
Quick Ratio 6.46
Altman-Z 3.88
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)115.59%
Cap/Depr(5y)151.67%
Cap/Sales(3y)19.87%
Cap/Sales(5y)20.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.6%
EPS Next Y-9.65%
EPS Next 2Y-6.69%
EPS Next 3Y-4.97%
EPS Next 5Y16.72%
Revenue 1Y (TTM)-29.16%
Revenue growth 3Y22.4%
Revenue growth 5Y11.88%
Sales Q2Q%-12.37%
Revenue Next Year1.15%
Revenue Next 2Y3.9%
Revenue Next 3Y16.85%
Revenue Next 5Y51.49%
EBIT growth 1Y-37.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.77%
EBIT Next 3Y-26.91%
EBIT Next 5YN/A
FCF growth 1Y-102.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.11%
OCF growth 3YN/A
OCF growth 5YN/A